Gastrointestinal Stromal Tumor Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Novartis, Cogent Biosciences, Plexxikon, Ariad Pharma, Exelixis

MLA

“Gastrointestinal Stromal Tumor Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Novartis, Cogent Biosciences, Plexxikon, Ariad Pharma, Exelixis.” M2 Presswire, 18 Oct. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.769361707&authtype=sso&custid=ns315887.

APA

Gastrointestinal Stromal Tumor Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Novartis, Cogent Biosciences, Plexxikon, Ariad Pharma, Exelixis. (2023, October 18). M2 Presswire.

Chicago

M2 Presswire. 2023. “Gastrointestinal Stromal Tumor Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Novartis, Cogent Biosciences, Plexxikon, Ariad Pharma, Exelixis,” October 18. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.769361707&authtype=sso&custid=ns315887.